<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-108794" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lemborexant</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ardeljan</surname>
            <given-names>Andrew D.</given-names>
          </name>
          <aff>Nova Southeastern University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hurezeanu</surname>
            <given-names>Razvan</given-names>
          </name>
          <aff>Kaiser Permanente</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Ardeljan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Razvan Hurezeanu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-108794.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Lemborexant is a medication used in the management and treatment of insomnia. It is in the dual orexin antagonist class of medications. This activity outlines the indications, actions, and contraindications for lemborexant as a valuable agent in managing insomnia. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as dosing, monitoring, and drug interactions pertinent for interprofessional team members in the care of patients with insomnia and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the management considerations for patients with insomnia.</p></list-item><list-item><p>Describe the mechanism of action of lemborexant.</p></list-item><list-item><p>Identify the most common adverse effects of lemborexant therapy.</p></list-item><list-item><p>Review the importance of collaboration and communication amongst the interprofessional team to enhance the delivery of care for patients receiving lemborexant.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=108794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=108794">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-108794.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Approved by the food and drug administration (FDA) in December of 2019, clinicians can use lemborexant to treat insomnia in adults. Additionally, lemborexant has been demonstrated to be safe for use in patients with mild obstructive sleep apnea (OSA).<xref ref-type="bibr" rid="article-108794.r1">[1]</xref> There are no other currently approved indications&#x000a0;for which lemborexant may be used, although it&#x000a0;is currently used to treat irregular sleep-wake rhythm in patients with Alzheimer disease is currently under investigation.<xref ref-type="bibr" rid="article-108794.r2">[2]</xref>&#x000a0;</p>
        <p>Lemborexant belongs to a class of drugs called dual receptor orexin antagonists (DORA), most of which are currently under evaluation in clinical trials, except for&#x000a0;suvorexant, which was FDA-approved for the treatment of primary insomnia in August of 2014.<xref ref-type="bibr" rid="article-108794.r3">[3]</xref></p>
      </sec>
      <sec id="article-108794.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The two variants of the orexin molecule (orexin A and orexin B) play an important role in the human sleep-wake cycles. Orexin A acts nonselectively to both the orexin-1 receptor (OX1R) and orexin-2 receptors (OX2R), while Orexin B acts more selectively on OX2R.<xref ref-type="bibr" rid="article-108794.r4">[4]</xref>&#x000a0;Produced in the hypothalamus, the orexin peptides are released from&#x000a0;between 50,000&#x000a0;and 80,000 orexin-producing neurons in the human brain. Additionally, these orexin-producing neurons project to various other neurons, some of which&#x000a0;are noradrenergic, serotonergic, dopaminergic, and cholinergic, supporting potential mechanisms of sleep-wake maintenance.<xref ref-type="bibr" rid="article-108794.r5">[5]</xref></p>
        <p>The wakefulness effects of orexins agonizing OX1R and OX2R are widely accepted and consistently supported in animal models. Additionally, the inhibition of both the OX1R and OX2R has demonstrated sedative characteristics in both human and animal models.&#x000a0;Unlike most current medications used to treat insomnia, which act on the gamma-aminobutyric acid (GABA) receptor, lemborexant presents a unique mechanism of action.<xref ref-type="bibr" rid="article-108794.r6">[6]</xref><xref ref-type="bibr" rid="article-108794.r7">[7]</xref>&#x000a0;Lemborexant is considered a DORA, exerting its sedative effects by reversible competitive binding to, and thus inhibiting, the wakefulness effects of orexin on OX1R and OX2R, with a stronger affinity to OX2R.&#x000a0;The time to peak concentration blood concentration of the drug is approximately 1 to 3 hours.<xref ref-type="bibr" rid="article-108794.r7">[7]</xref></p>
        <p>It has been proposed that taking advantage of this unique mechanism may come with fewer side effects than more commonly prescribed drugs to treat insomnia, such as benzodiazepines.&#x000a0;Current medications used to treat insomnia include benzodiazepines and "z-drugs," which act on the GABA receptor, antihistamines that&#x000a0;disrupt the wakeful effects of&#x000a0;histamine, and trazodone, which exerts its effects on both the serotonergic system and histamine receptors. Benzodiazepines present with a high potential for misuse and physical and psychological dependence.<xref ref-type="bibr" rid="article-108794.r8">[8]</xref> While still a relatively novel drug,&#x000a0;evidence suggests&#x000a0;lemborexant may be at least more effective with less potential for dependence than zolpidem, a non-benzodiazepine GABA receptor agonist.&#x000a0;Lemborexant effectively reduces sleep latency and increases maintenance compared to controls. Additionally, lemborexant appears to be more effective at improving sleep maintenance than zolpidem in patients with insomnia.<xref ref-type="bibr" rid="article-108794.r2">[2]</xref><xref ref-type="bibr" rid="article-108794.r9">[9]</xref>&#x000a0;Furthermore, there&#x000a0;is no evidence of withdrawal symptoms or associations with rebound insomnia upon withdrawal of either 5 mg or 10 mg&#x000a0;lemborexant&#x000a0;in both 30 day and 6-month trials.<xref ref-type="bibr" rid="article-108794.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-108794.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Normal Dosing Recommendations</bold>
</p>
        <p>Lemborexant&#x000a0;is administered&#x000a0;orally in doses of either 5 mg or 10 mg immediately before bed. Patients should not use lemborexant if they&#x000a0;anticipate waking up before 7 hours after&#x000a0;taking the medication so as not to experience dangerous impairment while awake. The maximum recommended clinical dose of lemborexant should not exceed 10 mg. Additionally, taking this medication with food or before&#x000a0;eating may delay its onset of action. Lemborexant is not meant for use in combination with alcoholic beverages. Furthermore, there is no available research on lemborexant in&#x000a0;pediatric populations or pregnant or breastfeeding women.</p>
      </sec>
      <sec id="article-108794.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of lemborexant include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Somnolence</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>CNS depressant effects/daytime impairment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sleep paralysis</p>
          </list-item>
          <list-item>
            <p>Hypnagogic/hypnopompic hallucinations</p>
          </list-item>
          <list-item>
            <p>Cataplexy-like symptoms</p>
          </list-item>
          <list-item>
            <p>Complex sleep behaviors</p>
          </list-item>
          <list-item>
            <p>Worsening of depression/suicidal ideation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-108794.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindication</bold>
</p>
        <p><bold>Narcolepsy</bold> is an absolute contraindication of lemborexant.</p>
        <p>
<bold>Drug Interactions or Dosing Modifications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Avoid:&#x000a0;Avoid taking lemborexant with strong&#x000a0;(itraconazole and clarithromycin) or moderate&#x000a0;(fluconazole and verapamil) CYP3A inhibitors, which may increase the adverse effects of lemborexant.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avoid: Avoid taking lemborexant with strong (rifampin, carbamazepine, and St. John&#x02019;s wort) or moderate (bosentan, efavirenz, etravirine, and modafinil) CYP3A inducers, which may reduce the effectiveness of lemborexant.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Use with caution:&#x000a0;Do not use a dose of greater than 5 mg&#x000a0;when co-administering with weak CYP3A inhibitors to avoid adverse effects.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Use with caution:&#x000a0;at doses greater than 5mg in patients over the age of 65.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mild hepatic impairment (Child-Pugh class A):&#x000a0;May experience increased somnolence, but there is no recommended dose adjustment.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Moderate hepatic impairment (Child-Pugh class B):&#x000a0;A nightly dose greater than 5 mg is not recommended in patients with moderate hepatic impairment.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe hepatic impairment (Child-Pugh class C):&#x000a0;Researchers have not studied lemborexant in severe hepatic impairment, and therefore the current recommendation for such patients is to avoid using the drug.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-108794.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The elimination half-life of lemborexant was 17 hours and 19 hours in 5 mg and 10 mg doses, respectively. Age, body mass index (BMI), race, or sex have no impact on the elimination half-life of the drug. There are no dosage adjustment recommendations in patients with mild, moderate, or severe renal impairment, although patients with severe renal illness may experience excessive somnolence.&#x000a0;</p>
        <p>Compared&#x000a0;to the more popular hypnotic drug zolpidem,&#x000a0;lemborexant appears to&#x000a0;exhibit far less potential for misuse. Patients who use it do not appear to be at risk for developing dependence or withdrawal symptoms. This characteristic may indicate that lemborexant may be a safer option for patients with a history of addiction or drug abuse. Nonetheless, lemborexant is a Schedule IV-controlled substance with sedative properties and should be used and prescribed with caution. Further research is warranted to investigate the abuse potential for lemborexant. Furthermore, lemborexant should be compared to commonly prescribed GABA agonists other than zolpidem, particularly hypnotic benzodiazepines, as current evidence suggests it may be a safer option.&#x000a0;</p>
      </sec>
      <sec id="article-108794.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinical evidence to support toxic doses of lemborexant in humans is scarce. In at least one clinical study, 7.5 times the recommended dose of lemborexant was given to healthy human subjects resulting in dose-dependent increases of somnolence frequency, providing little information regarding toxicity. There is no specific antidote to lemborexant overdose. In the case of a suspected overdose, the protocol of any drug overdose should be followed, with close monitoring from a medical professional.</p>
      </sec>
      <sec id="article-108794.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing insomnia with lemborexant requires&#x000a0;communication between interprofessional healthcare team members,&#x000a0;including clinicians, pharmacists, nurses, and other healthcare assistants. Patients should be aware of the possible risks of using lemborexant, especially those with pre-existing conditions such as drug abuse disorder or hepatic impairment. While lemborexant appears to be a safe option for treating insomnia in adults, it is a schedule IV-controlled substance and should be treated by patients and healthcare providers as such. Additionally, further randomized controlled trials are warranted due to the novelty and apparent advantages of lemborexant compared to current treatments. Lemborexant utilizes&#x000a0;a novel mechanism of action, potentially&#x000a0;presenting a superior safety profile for adults receiving pharmaceutical treatment for insomnia.<xref ref-type="bibr" rid="article-108794.r7">[7]</xref><xref ref-type="bibr" rid="article-108794.r10">[10]</xref><xref ref-type="bibr" rid="article-108794.r2">[2]</xref>&#x000a0;[Level 1]</p>
        <p>Patient education and post-prescribing monitoring with lemborexant are best accomplished with an interprofessional healthcare team exercising collaborative activity and open information sharing to drive optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-108794.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=108794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=108794">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/108794/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=108794">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-108794.s11">
        <title>References</title>
        <ref id="article-108794.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Filippov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moline</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zammit</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Bsharat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study.</article-title>
            <source>J Sleep Res</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>e13021</fpage>
            <pub-id pub-id-type="pmid">32187781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Lemborexant: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <page-range>425-432</page-range>
            <pub-id pub-id-type="pmid">32096020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rhyne</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Suvorexant in insomnia: efficacy, safety and place in therapy.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>189</fpage>
            <page-range>189-95</page-range>
            <pub-id pub-id-type="pmid">26478806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakurai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuzaki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chemelli</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kozlowski</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arch</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Buckingham</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Annan</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>McNulty</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Terrett</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Elshourbagy</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Bergsma</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.</article-title>
            <source>Cell</source>
            <year>1998</year>
            <month>Feb</month>
            <day>20</day>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-85</page-range>
            <pub-id pub-id-type="pmid">9491897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peyron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tighe</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>van den Pol</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>de Lecea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Sutcliffe</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kilduff</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Neurons containing hypocretin (orexin) project to multiple neuronal systems.</article-title>
            <source>J Neurosci</source>
            <year>1998</year>
            <month>Dec</month>
            <day>01</day>
            <volume>18</volume>
            <issue>23</issue>
            <fpage>9996</fpage>
            <page-range>9996-10015</page-range>
            <pub-id pub-id-type="pmid">9822755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asnis</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians.</article-title>
            <source>Int J Mol Sci</source>
            <year>2015</year>
            <month>Dec</month>
            <day>30</day>
            <volume>17</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">26729104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moline</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zammit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pinner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dhadda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Giorgi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Satlin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>15</day>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1289</fpage>
            <page-range>1289-1299</page-range>
            <pub-id pub-id-type="pmid">29065953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fluyau</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Revadigar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Manobianco</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2018</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>147</fpage>
            <page-range>147-168</page-range>
            <pub-id pub-id-type="pmid">29713452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bouchette</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Akhondi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Quick</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Zolpidem</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">28723037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108794.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zammit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mayleben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dhadda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Filippov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>LoPresti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moline</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.</article-title>
            <source>JAMA Netw Open</source>
            <year>2019</year>
            <month>Dec</month>
            <day>02</day>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>e1918254</fpage>
            <pub-id pub-id-type="pmid">31880796</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
